Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03129373
Other study ID # 14E2344
Secondary ID
Status Completed
Phase N/A
First received April 3, 2017
Last updated September 18, 2017
Start date July 2015
Est. completion date November 2016

Study information

Verified date September 2017
Source Oystershell NV
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present study was set-up to evaluate clinical efficacy of Pixie® cryogenic pen versus two comparator cryogenic products (Wartner® and Wortie®) for the treatment of common and plantar warts.


Description:

The use of cryotherapy has been long known to be effective against warts. The indications for Pixie® are in line with the indications presented in the collected literature data, as well as with the indications of equivalent devices.

The benefits of warts treatment without the use of chemicals are clearly evidenced. The treatment period is much shorter (one treatment compared to daily application of keratinolytics or fluorouracil, over a period of a few weeks). The cryogen therapy application through a conic tip is much more precise than with chemical substances. Chemical substance application is leading to more side effects of the surrounding skin (typical for chemical treatment are pain, blistering, ulceration and contact dermatitis).

The Instructions for Use were developed in line with these data and are therefore covering all hazards known up to the date of this report.

Based on these data the product received its CE-mark approval


Recruitment information / eligibility

Status Completed
Enrollment 138
Est. completion date November 2016
Est. primary completion date November 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 4 Years and older
Eligibility Inclusion Criteria:

- Healthy subject.

- Sex: male or female.

- Age: more than 4 years old.

- Subject presenting at least 1 new common wart on hand or on feet or plantar wart (wart present since less than 6 months).

- Subject, including minors aged more than 14 years, having given freely and expressly his/her informed consent.

- Minor whose legal guardians have given their free and express informed consent.

- Subject who is able to comply with the study requirements, as defined in the present protocol, at the Investigator's appreciation.

- Subject able to comply with protocol requirements, as defined in the protocol.

- Subject or child's legal guardians being affiliated to a health social security system.

- Female subjects of childbearing potential should use a medically accepted contraceptive regimen (at the Investigator's discretion) since at least 12 weeks before the beginning of the study, during all the study.

Exclusion Criteria:

- Pregnant, parturient or nursing woman or planning a pregnancy during the study.

- Subject who had been deprived of their freedom by administrative or legal decision.

- Subject in a social or sanitary establishment.

- Major subject who is under guardianship or who is not able to express his consent.

- Subject suspected to be non-compliant according to the Investigator's judgment.

- Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results.

- Subject with a cutaneous disease other than common and plantar warts, on the studied zone.

- Subject with a known allergy to one of the component of the products or to the comparator.

- Subject who has diabetes.

- Subject having problems with blood circulation, or having a blood clotting condition.

- Subject with immune deficiency or autoimmune disease.

- Subject presenting more than 10 warts on the body.

- Subject presenting bleeding warts.

- Subject presenting birthmarks, moles, warts with hairs growing from them, or any other spots.

- Subject having a sensitive skin, inflamed, infected, irritated, red, damaged, cut, grazed, diseased or itchy on the treated zone.

- Subject presenting genital warts, flat warts, filiform warts, periungual warts or warts larger than 0.8cm.

- Subject undergoing a topical treatment on the test area or a systemic treatment:

- immunosuppressors and/or corticoids during the 4 previous weeks and during the study,

- retinoids during the 6 previous months and during the study,

- any medication stabilized for less than one month.

- Subject who received a treatment of any type on the selected wart during the previous 6 months.

- Intensive exposure to sunlight or UV-rays on the studied zone within the previous month and/or foreseen during the study.

- Subject planning to change her/his life habits during the study.

- Subjects must not take part in any other clinical study whilst taking part in this study.

- Subjects must not deliberately "sunbathe" for the duration of the study on the studied zone in case they cannot cover the treated area from sunlight.

- No product (except usual hygiene products and except for the prescribed after treatment) is to be used on the selected wart during the study. The subjects will continue to use their usual hygiene products, but they must not change the brand or use new products throughout the course of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Cryogenic treatment of warts
Treatment of common and plantar wart by cryotherapy treatment.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Oystershell NV

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of the percentage of subjects with clinical wart remission after 1 treatment in the Pixie® group versus comparators groups (Wartner® and Wortie®), as observed during a clinical evaluation of the treated wart by the dermatologist. After 1 treatment (approximately 15 days after the first treatment)
Secondary Comparison of the number of treatments needed for clinical remission of warts with the three products. 1 treatment (day 0), 2 treatments (day 15), 3 treatments (day 29)
Secondary Surface area measurements of frostbite area to evaluate the efficacy of the freezing process, during the three applications if applicable. Measurement immediately after treatment, with a tape measure device of the frostbite on the skin, created by cryothereapy treatment (measure in cm) 1 treatment (day 0), 2 treatments (day 15), 3 treatments (day 29)
Secondary Illustration of the visual aspects of the wart remission with macrophotographs. Macrophotographs taken with a Nikon D90 apparatus and a standardization device for the repositionning Before treatment (day 0 before treatment), after 1 treatment (day 15), after 2 treatments (day 29), after 3 treatments (day 45)
Secondary Evaluation of the skin conditions at study end, assessed by the investigator by clinical evaluation. Evaluation of the skin color after treatment. Before treatment (day 0 before treatment), after 1 treatment (day 15), after 2 treatments (day 29), after 3 treatments (day 45)
Secondary Recording of adverse events. On days 0, 3, 15, 29 and 45
Secondary Comparison of the percentage of subjects with clinical wart remission after 1, 2 and 3 treatments in the Pixie® group versus comparators groups (Wartner® and Wortie®), as observed during a clinical evaluation of the treated wart by the dermatologist. After 1 treatment (day 15), after 2 treatments (day 29), after 3 treatments (day 45)
See also
  Status Clinical Trial Phase
Completed NCT01757392 - Candin Safety & Efficacy Study for the Treatment of Warts Phase 2
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Withdrawn NCT00546611 - The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s) Phase 1
Completed NCT00117871 - Study With a Topical Gel to Treat Common Warts in Adults Phase 2
Completed NCT04278573 - Intralesional Vitamin D Injection for Treatment of Common Warts Phase 2
Completed NCT02231879 - Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Phase 2/Phase 3
Completed NCT06309420 - Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts N/A
Not yet recruiting NCT05617950 - Salicylic Acid Versus Cryotherapy for the Treatment of HPV1-induced Plantar Warts N/A
Not yet recruiting NCT05616078 - Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts N/A
Recruiting NCT01712295 - 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Phase 4
Active, not recruiting NCT00254280 - Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light - a Randomized Controlled Trial N/A
Completed NCT04781244 - Cost-effectiveness of EndWarts® FREEZE - an Alternative Home Cryotherapy Device for Wart Treatment N/A
Completed NCT01101750 - Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Phase 4
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Recruiting NCT05625633 - Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts Phase 2/Phase 3
Completed NCT02393417 - Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) Phase 2
Completed NCT01808443 - Efficacy of Laser Versus Cryotherapy in the Treatment of Warts N/A
Completed NCT00116675 - Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2
Completed NCT00116662 - An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2